tbuckley/cabot-search huggingface dataset:
Expanding the Lung Donor Pool and Improving Outcomes
Authors: Stephen Chiu, Sara E. A. Mills, Ankit Bharat
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Mutations in the Telomerase Complex and Expression Levels of the TERT Gene Determine Severity and Outcome of Disease in Aplastic Anemia Patients
Authors: Arati Khanna-Gupta, Durga Sarvepalli, Snigdha Majumder, Coral Karunakaran, Malini Manoharan, Shilpa Prabhu, Varun Bafna, Sakthivel Murugan SM, Chirantan Bose, Ravi Gupta, Nataraj KS, Sharat Damodar, Arkasubhra Ghosh
Journal: Blood (2016)
CRLF2 Overexpression Demonstrates Enhanced Leukemogenicity in Down Syndrome Hematopoietic Cells
Authors: Jacob J. Junco, Shan Liang, Vishal Gokani, Vincent Ulysses Gant, Jaime Munoz, Allison Mayle, Chun Shik Park, H. Daniel Lacorazza, Margaret A Goodell, Karen R. Rabin
Journal: Blood (2016)
Acupuncture Prophylaxis of Cancer Chemotherapy-Induced Sickness
Authors: J W Dundee, R G Ghaly, K T J Fitzpatrick, W P Abram, G A Lynch
Journal: Journal of the Royal Society of Medicine (1989)

In a multi-facet study we evaluated the efficacy of P6 electroacupuncture (10 Hz applied for 5 min) as an antiemetic in patients receiving a variety of cancer chemotherapy drugs. The study involved 130 (15 in an open pilot study, 10 in a randomized placebo controlled crossover study and 105 in a definitive study) patients who had a history of distressing sickness after previous treatment, and who, on the basis of a previous survey, would be expected to have a 96% chance of this with subsequent therapy. Sickness was either completely absent or reduced considerably in 97% of patients and no side effects were encountered. The limited crossover study, using a ‘dummy’ acupuncture (ACP) point showed that the beneficial effects were limited to the P6 point. Logistic and ethical considerations excluded the possibility of carrying out a larger placebo-controlled study. While in our hands P6 ACP was an effective antiemetic in patients having cancer chemotherapy, because of the time involved and the brevity of the action (8 h) an alternative approach to electro-ACP is required before this technique is adopted clinically.
Redefinition of Hypereosinophilic Disorders Based on an Analysis of 28 Cases of FIP1 L1-PDGFRA Negative Persistent Unexplained Eosinophilia (PUE) with Eosinophil End-Organ Damage (EEOD).
Authors: Finella Brito-Babapulle, Nicholas C.P. Cross
Journal: Blood (2007)
A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia
Authors: T. M. Kadia, G. Borthakur, W. Wierda, F. Ravandi, S. Faderl, W. Newsome, J. Zwiebel, M. Egorin, G. Garcia-Manero
Journal: Journal of Clinical Oncology (2007)

7066 Background: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor (HDACi) with single agent activity in patients with advanced leukemia. HDACi lead to the acetylation of histones and facilitate an open chromatin configuration. Idarubicin potently inhibits DNA topoisomerase (topo) II by forming stable complexes with it, and eventually leading to ds-DNA breaks and apoptosis. Because of their effect on the chromatin of dividing cells, we postulated that the pairing of an HDACi with a topo II inhibitor, would have antileukemia activity. We tested this in vitro in leukemia cell lines and have shown that the combination of idarubicin and SAHA is synergistic. Methods: To test this clinically, we developed a phase I trial of the combination of idarubicin and SAHA, given in 2 different schedules, in advanced leukemia. In schedule A, idarubicin 12 mg/m 2 daily for 3 days is given concurrently with SAHA, orally TID for 14 days (starting at 100 mg). In schedule B, SAHA is only given for 3 days. Only SAHA was dose-escalated, following a classic 3+3 schema, with the plan to treat 10 patients at the MTD. If both schedules were open at any given time, patients were randomized among them. Results: So far, 20 patients have been treated: 8 in schedule A and 12 in B. Median age of the patients is 56 (21–80). Of the patients enrolled thus far, 19 (95%) had relapsed, refractory AML, 1 had MDS, and 8 out of the 20 (40%) had diploid cytogenetics. In schedule A, a dose of idarubicin at 12 mg/m 2 and SAHA at 100 mg was found to be above the MTD, with the DLT's being myelosuppression, encephalopathy, and dysphagia. Dose escalation of schedule B continues currently at a dose of SAHA at 400 mg. No severe grade 3 or 4 toxicities have been observed on this schedule. No cardiac toxicity has been observed. So far, 2 CR and 2 complete marrow responses have been observed. All of these patients had failed previous anthracycline-based chemotherapy. Induction of γ-H2AX, histone acetylation, and induction of topo II and p21CIP1 mRNA expression are being evaluated, as well as pharmacokinetic characteristics of both agents. Conclusion: The combination of idarubicin with SAHA is safe and active, and SAHA could be incorporated in the treatment of front-line AML. No significant financial relationships to disclose.
Spontaneous glioma-induced seizures recorded in a living human brain tissue preparation
Authors: Alastair Kirby, Jose Pedro Lavrador, Christian Brogna, Francesco Vergani, Bassel Zebian, Christopher Chandler, Istvan Bodi, Ranjeev Bhangoo, Ashkan Keyoumars, Gerald Finnerty
Journal: Neuro-Oncology (2019)

Abstract Gliomas often present clinically with seizures. Tumour-associated seizures can be difficult to control with medication. A deeper understanding of the cellular mechanisms underlying tumour-associated seizures would provide a basis for developing new treatments. Here, we investigate epileptic discharges in peritumoral cortex using living human brain tissue donated by people having a craniotomy for glioma resection (REC approval, 18/SW/002). The brain tissue was cut into thin slices, which preserved the architecture of the glioma and the adjacent healthy brain. The brain slices were incubated in 5-aminolevulinic acid to make the glioma cells fluorescent. This enabled us to make electrophysiological recordings of brain activity across the boundary between glioma and brain. We recorded from brain slices of 5 participants with glioblastoma and 4 participants with oligodendroglioma (WHO grade II – III). Spontaneous “seizure-like” discharges were recorded in brain slices from 5/8 participants (3 GBM, 2 oligodendroglioma) who reported seizures and from one participant (GBM) who had not had any clinical seizures. Further analysis of the seizure-like discharges revealed that they could be subdivided into two distinct types based on the major frequencies in the discharge. We concluded that human brain slices from people with either a low-grade or a high-grade glioma can generate spontaneous seizure-like discharges. The living human brain tissue preparation gives us a platform to study the mechanisms of tumour-associated seizures and how abnormal neural activity affects glioma growth.
Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen
Authors: Hassan Sibai, Fotios V. Michelis, Nada Hamad, Jieun Uhm, Vikas Gupta, John G. Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel, Dennis Dong Hwan Kim
Journal: Blood (2014)
Tie2+ Bone Marrow Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo.
Authors: Phuong L. Doan, J. Lauren Russell, Sarah K. Meadows, Heather A Himburg, Pamela Daher, Nelson J. Chao, David G. Kirsch, John P. Chute
Journal: Blood (2009)
Delta-like Ligands Expressed By Stromal Cells in Secondary Lymphoid Organs Deliver an Early Pulse of Notch Signaling and Drive T Cell Pathogenicity in Acute Graft-Versus-Host Disease
Authors: Jooho Chung, Christen L. Ebens, Vedran Radojcic, Ute Koch, Ann Friedman, Ivy T. Tran, Qian Chai, Lucas Onder, Minhong Yan, Pavan Reddy, Bruce R. Blazar, Burkhard Ludewig, Christian W. Siebel, Freddy Radtke, Ivan Maillard
Journal: Blood (2014)
Second Allogeneic Transplants for Relapsed Acute Lymphoblastic Leukemia Result in High Response Rates of Short Duration: Further Intervention Is Required to Maintain Response.
Authors: Partow Kebriaei, Rima Saliba, Gabriela Rondon, Laura Worth, Laurence J.N. Cooper, Deborah A. Thomas, Hagop Kantarjian, Marcos de Lima, Richard E Champlin, Sergio Giralt
Journal: Blood (2009)
Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.
Authors: Richard C. Harvey, Brent L. Wood, I-Ming Chen, Michelle Y Doral, Kristie Yu, Meenakshi Devidas, Julie M. Gastier-Foster, Eric C. Larsen, Kelly W. Maloney, Elizabeth Raetz, Naomi Winick, William L. Carroll, Stephen P. Hunger, Cheryl L Willman, Mignon L. Loh
Journal: Blood (2012)
Loss of Wild-Type Kras is Associated with Enhanced Fitness and Increased Mitogen-Activated Protein Kinase Pathway Addiction in K-RasG12D Acute Myeloid Leukemia
Authors: Michael R. Burgess, Eugene Hwang, Anica M. Wandler, Saurabh Asthana, Elizabeth M. Davis, Michelle M. Le Beau, Barry Taylor, Kevin Shannon
Journal: Blood (2014)
A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Phase II Study of Oral Fludarabine in Untreated B-Cell Chronic Lymphocytic Leukemia.
Authors: C. Shustik, R. Turner, P. Desjardins, L. Fernandez, S. Rubin, L. Larratt, A. Duncan, D. Rizi, A. Sadura, L. Shepherd, D. Li, L. Rassenti, T. Kipps
Journal: Blood (2005)
Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD)
Authors: Fernando Ramos, Carmen Pedro, Jose-Maria Garcia-Ruiz-de-Morales, Eva Barragan, Raquel de Paz, Andres Insunza, Mar Tormo, Maria Diez-Campelo, Blanca Xicoy, Eduardo Salido, Javier Sanchez-del-Real, Leonor Arenillas, Carlos Santamaria, Noemi Puig, Lourdes Florensa, Francesc Sole, Marcos González, Elisa Luño, Guillermo F Sanz
Journal: Blood (2012)
Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).
Authors: Renato Bassan, Orietta Spinelli, Elena Oldani, Manuela Tosi, Barbara Peruta, Erika Borlenghi, Enrico Maria Pogliani, Eros Di Bona, Vincenzo Cassibba, Anna Maria Scattolin, Claudio Romani, Fabio Ciceri, Agostino Cortelezzi, Giacomo Gianfaldoni, Daniele Mattei, Ernesta Audisio, Tamara Intermesoli, Alessandro Rambaldi
Journal: Blood (2012)
Superior Identification of Prognostic Relevant Copy Number Abnormalities By SNP-Based Genomic Arrays As Compared to Interphase FISH in Multiple Myeloma
Authors: Marian Stevens-Kroef, Daniel Olde Weghuis, Simone Wezenberg, Sandra Croockewit, Hans Wessels, Marjolein van der Mespel, Sonja Zweegman, Pino J. Poddighe
Journal: Blood (2016)
A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.
Authors: Andreas Hochhaus, Oliver G. Ottmann, STephanie Lauber, Timothy Hughes, Gregor Verhoef, Anthony P. Schwarer, Alois Gratwohl, Teresa Rafferty, Debra Resta, Norbert Gattermann
Journal: Blood (2006)
Meningeal γδ T cell–derived IL-17 controls synaptic plasticity and short-term memory
Authors: Miguel Ribeiro, Helena C. Brigas, Mariana Temido-Ferreira, Paula A. Pousinha, Tommy Regen, Cátia Santa, Joana E. Coelho, Inês Marques-Morgado, Cláudia A. Valente, Sara Omenetti, Brigitta Stockinger, Ari Waisman, Bruno Manadas, Luísa V. Lopes, Bruno Silva-Santos, Julie C. Ribot
Journal: Science Immunology (2019)

Meningeal γδ T cells are biased toward IL-17 production and control hippocampal synaptic plasticity and short-term memory.
Latent Cardiogenic Potential in Endocardium and Hemogenic Endothelium Revealed in the Absence of Scl/tal1
Authors: Amelie Montel-Hagen, Ben Van Handel, Roberto Ferrari, Rajkumar Sasidharan, Tonis Org, Kees Boogerd, Haruko Nakano, Jian Zhou, Xinmin Li, Matteo Pellegrini, Stuart H. Orkin, Austin Nakano, Siavash Kurdistani, Sylvia Evans, Hanna Mikkola
Journal: Blood (2011)
Targeted Gene Modification In Hematopoietic Stem Cells: A Potential Treatment For Thalassemia and Sickle Cell Anemia
Authors: Andreas Reik, Kai-Hsin Chang, Sandra Stehling-Sun, Yuanyue Zhou, Gary K Lee, Lynn Truong, Travis Wood, Ziying Zhang, Albert Luong, Andy Chan, Pei-Qi Liu, Jeffrey C Miller, David E Paschon, Dmitry Y Guschin, Lei Zhang, Evangelia Yannaki, Martin A Giedlin, Edward J Rebar, Philip D Gregory, Fyodor D Urnov, Thalia Papayannopoulou, George Stamatoyannopoulos
Journal: Blood (2013)
Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence By Overcoming the Host Histocompatibility Barrier
Authors: Matthieu Bauer, Raedun Clarke, Jeffrey Sasaki, Brian Groff, Tom Tong Lee, Weijie Lan, Ramzey Abujarour, Greg Bonello, Michelle Burrascano, Megan Robinson, Ryan Bjordahl, Svetlana Gaidarova, Stewart E. Abbot, Scott Wolchko, Daniel Shoemaker, Bahram Valamehr
Journal: Blood (2016)
Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.
Authors: M. de Lima, D. Couriel, M. Munsell, M. Westmoreland, H. Shah, J. deJesus, C. Hosing, S. Ghosh, P. Anderlini, J. Gajewski, B. Andersson, S. Kornblau, B. Hocking, C. Ippoliti, S. Giralt, E. Shpall, R. Champlin
Journal: Blood (2004)
CD62E-Positive Endothelial Microparticle-Neutrophil Conjugates, a Novel Marker of Prothrombotic and Inflammatory Disorders.
Authors: Julio A. Chirinos, Wenche Jy, Andres O. Soriano, Aurelio Castrellon, Freddy Del Carpio, Roque Arteaga, Gustavo A. Heresi, Joaquin J. Jimenez, Lawrence L. Horstman, Yeon S. Ahn
Journal: Blood (2005)
The Role of PET/TC in the Full Range of Monoclonal Gammopathies
Authors: Rafael Ríos Tamayo, Juan Sáinz Pérez, Jose Manuel Puerta Puerta, Rosario Leyva Ferrer, Youssef Moatassim de la Torre, Pilar López Garrido, José María de Pablos Gallego, Alvaro Miguel Alba Sosa, Elisa Lopez Fernandez, Lucia Moratalla Lopez, Antonio Romero Aguilar, Manuel Jurado, Jose Manuel Llamas Elvira, Antonio Rodriguez Fernandez, Rocio Sanchez Sanchez
Journal: Blood (2014)
The Results of the Russian Clinical Trial of Mesenchymal Stromal Cells (MSCs) in Severe Neutropenic Patients (pts) with Septic Shock (SS) (RUMCESS trial)
Authors: Gennadii M. Galstian, Elena N. Parovichnikova, Polina M. Makarova, Larisa A. Kuzmina, Vera V. Troitskaya, Eduard Gemdzhian, Nina I. Drize, Valeri G. Savchenko
Journal: Blood (2015)
The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype
Authors: Heinz Ludwig, Ladan Mirbahai, Niklas Zojer, Arthur Bradwell, Stephen Harding
Journal: Blood (2010)
Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation
Authors: Nelson Leung, Shaji Kumar, Angela Dispenzieri, Martha Lacy, Francis Buadi, David Dingli, William J Hogan, Dennis Gastineau, Morie Gertz
Journal: Blood (2010)
CD44 Monoclonal Antibody-Enhanced Clearance Of Chronic Myeloid Leukemia Stem Cells From The Malignant Niche
Authors: Eva Hellqvist, Frida Holm, Cayla N Mason, Valeria Runza, Stefan Weigand, Anil Sadarangani, Catriona H.M. Jamieson
Journal: Blood (2013)
New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).
Authors: Amrita Krishnan, Andrew Raubitschek, Stephen J. Forman, Henry Fung, Arturo Molina, David Yamauchi, Peter Falk, Ricardo Spielberger, Leslie Popplewell, Roberto Rodriguez, Pablo Parker, Warren Chow, Ryoto Nakamura, Auayporn Nademanee
Journal: Blood (2005)
Donor-Type Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Common Cause of Late Graft Failure in Patients with Complete Donor Chimerism
Authors: Kana Maruyama, Hiroyuki Maruyama, Yoshitaka Zaimoku, An T. T. Dao, Takamasa Katagiri, Hirohito Yamazaki, Shinji Nakao
Journal: Blood (2014)
Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib
Authors: Eri Matsuki, Takashi Kumagai, Koiti Inokuchi, Kazuteru Ohashi, Atsushi Shinagawa, Jin Takeuchi, Chikashi Yoshida, Shinichiro Okamoto, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Kaichi Nishiwaki, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki
Journal: Blood (2012)
Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.
Authors: Tanja Heimberger, Mindaugas Andrulis, Stephanie Fischbach, Thorsten Stühmer, Hermann Einsele, Ralf C. Bargou, Manik Chatterjee
Journal: Blood (2009)
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
Authors: Brian A. Bergmark, Pieter W. Kamphuisen, Stephen D. Wiviott, Christian T. Ruff, Elliott M. Antman, Francesco Nordio, Julia F. Kuder, Michele F. Mercuri, Hans J. Lanz, Eugene Braunwald, Robert P. Giugliano
Journal: Circulation (2019)

Numerous scales exist for the classification of major bleeding events. Limited data compare the most commonly used bleeding scales within a single at-risk cohort of patients with atrial fibrillation. Here, we analyze bleeding outcomes according to the ISTH (International Society on Thrombosis and Hemostasis), TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Usage of Strategies to Open Occluded Arteries), and BARC (Bleeding Academic Research Consortium) bleeding scales in the ENGAGE AF (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation)-TIMI 48 trial (NCT00781391) of edoxaban versus warfarin.A total of 21 105 patients with atrial fibrillation at risk for stroke (CHADS2 score ≥2) were enrolled in the ENGAGE AF-TIMI 48 trial comparing warfarin with a higher- (60/30 mg daily) or lower- (30/15 mg daily) dose edoxaban regimen. Median follow-up was 2.8 years. Bleeding events occurring among on-treatment patients were examined. Annualized event rates were calculated by the ISTH, TIMI, GUSTO, and BARC scales and compared across treatment arms. Cox proportional hazards for a first bleeding event of each type were calculated for higher-dose edoxaban regimen vs warfarin and lower-dose edoxaban regimen versus warfarin.A total of 10 311 bleeding events were reported. In a comparison of the most severe events in each scale, ISTH major bleeding was the most common (n=1289), followed by TIMI major (n=548), GUSTO severe/life-threatening (n=347), and BARC 3c+5 (n=276) bleeding. Lower bleeding risk with edoxaban compared with warfarin was seen regardless of bleeding scale (higher-dose edoxaban regimen range: hazard ratio [HR], 0.47 [95% CI, 0.35-0.62] for BARC 3c+5 versus HR, 0.80 [95% CI, 0.71-0.91] for ISTH major; lower-dose edoxaban regimen range: HR, 0.32 [95% CI, 0.23-0.45] for BARC 3c+5 versus HR, 0.47 [95% CI, 0.41-0.55] for ISTH major). Furthermore, a gradient of more pronounced risk reduction with edoxaban was observed with greater severity of first bleeding event (higher-dose edoxaban regimen: HR, 0.47 [95% CI, 0.35-0.62] for BARC 3c+5 bleeds versus HR, 0.86 [95% CI, 0.81-0.91] for any BARC bleed; lower-dose edoxaban regimen: HR, 0.32 [95% CI, 0.23-0.45] for BARC 3c+5 bleeds versus HR, 0.68 [95% CI, 0.63-0.72] for any BARC bleed). The direction of this trend was consistent for both gastrointestinal bleeding and nongastrointestinal bleeding.Among patients with atrial fibrillation at risk for stroke, there was a >4-fold difference in the frequency of the most severe bleeding events across commonly used bleeding scales. Furthermore, the relative safety of edoxaban compared with warfarin tended to increase with greater severity of bleeding.URL: https://www.clinicaltrials.gov. Unique identifier: NCT00781391.
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)
Authors: Giampaolo Merlini, Vaishali Sanchorawala, Zonder A Jeffrey, Vishal Kukreti, Stefan O Schoenland, Arnaud Jaccard, Angela Dispenzieri, Adam D. Cohen, Deborah Berg, Zheng Yuan, Ai-Min Hui, Palladini Giovanni, Raymond L. Comenzo
Journal: Blood (2014)
Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).
Authors: Kieron Dunleavy, Alan S. Wayne, Richard Little, Nicole Grant, Seth Steinberg, Elaine S. Jaffe, Stefania Pittaluga, Robert Yarchoan, Jorge Carrasquillo, John Janik, Wyndham H. Wilson
Journal: Blood (2006)
Diseases of the Nervous System. A Text-Book for Students and Practitioners of Medicine.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.
Authors: María Rozman, Susana G. Kalko, Jordi Esteve, Mireia Camós, Josep-Lluís Aguilar, Montserrat Torrebadell, Dolors Costa, Ana Carrió, Pedro Jares, Emili Montserrat, Elías Campo
Journal: Blood (2006)